Edwards Lifesciences Corporation (NYSE:EW) Short Interest Update

Edwards Lifesciences Corporation (NYSE:EW) saw a large decline in short interest in the month of September. As of September 15th, there was short interest totaling 7,260,000 shares, a decline of 29.9% from the August 31st total of 10,350,000 shares. Based on an average daily volume of 4,350,000 shares, the short-interest ratio is presently 1.7 days. Approximately 1.3% of the company’s shares are sold short. Approximately 1.3% of the company’s shares are sold short. Based on an average daily volume of 4,350,000 shares, the short-interest ratio is presently 1.7 days.

Wall Street Analyst Weigh In

A number of research firms have weighed in on EW. Piper Sandler upped their target price on Edwards Lifesciences from $83.00 to $90.00 and gave the stock an “overweight” rating in a report on Friday, July 25th. Wells Fargo & Company upped their price target on Edwards Lifesciences from $84.00 to $88.00 and gave the stock an “overweight” rating in a research note on Thursday, August 7th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Saturday, September 27th. William Blair raised shares of Edwards Lifesciences to a “strong-buy” rating in a research report on Friday, July 25th. Finally, Mizuho upped their target price on shares of Edwards Lifesciences from $87.00 to $95.00 and gave the stock an “outperform” rating in a research report on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $87.06.

Edwards Lifesciences Trading Up 0.2%

NYSE EW opened at $76.70 on Wednesday. Edwards Lifesciences has a 12 month low of $64.51 and a 12 month high of $83.00. The stock’s fifty day moving average price is $78.39 and its 200-day moving average price is $76.05. The stock has a market cap of $45.03 billion, a P/E ratio of 11.04, a P/E/G ratio of 3.68 and a beta of 1.05. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the prior year, the firm posted $0.70 EPS. Edwards Lifesciences’s revenue for the quarter was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, equities analysts forecast that Edwards Lifesciences will post 2.45 EPS for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of the business’s stock in a transaction on Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the transaction, the vice president directly owned 22,002 shares of the company’s stock, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Larry L. Wood sold 8,950 shares of the business’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the transaction, the insider owned 206,900 shares in the company, valued at $16,150,614. This represents a 4.15% decrease in their position. The disclosure for this sale can be found here. 0.34% of the stock is owned by insiders.

Institutional Trading of Edwards Lifesciences

Institutional investors have recently added to or reduced their stakes in the business. Brighton Jones LLC purchased a new stake in shares of Edwards Lifesciences during the fourth quarter valued at $266,000. Merit Financial Group LLC boosted its holdings in shares of Edwards Lifesciences by 93.4% during the 1st quarter. Merit Financial Group LLC now owns 10,793 shares of the medical research company’s stock valued at $782,000 after acquiring an additional 5,212 shares during the last quarter. Gateway Investment Advisers LLC boosted its holdings in shares of Edwards Lifesciences by 2.9% during the 1st quarter. Gateway Investment Advisers LLC now owns 11,917 shares of the medical research company’s stock valued at $864,000 after acquiring an additional 336 shares during the last quarter. Wedmont Private Capital boosted its holdings in shares of Edwards Lifesciences by 18.1% during the 1st quarter. Wedmont Private Capital now owns 9,860 shares of the medical research company’s stock valued at $684,000 after acquiring an additional 1,512 shares during the last quarter. Finally, RDA Financial Network boosted its holdings in shares of Edwards Lifesciences by 2.7% during the 1st quarter. RDA Financial Network now owns 34,696 shares of the medical research company’s stock valued at $2,515,000 after acquiring an additional 926 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.